Updated Articles for Listserv
Medicare Updated Articles Display Page
Article ID | Modified By | Modified On | Title |
---|---|---|---|
29093830 | Kirby Schwartzbauer | 02/10/2025 08:50:50 | Open Public Meeting Announcement - Allergy Immunotherapy (AIT) with Subcutaneous Immunotherapy (SCIT) - March 6, 2025 |
29093978 | James Marko | 02/10/2025 10:11:54 | Allergen Immunotherapy (AIT) with Subcutaneous Immunotherapy (SCIT) - Published for Review and Comments |
29093996 | James Marko | 02/10/2025 10:11:55 | Allergen Immunotherapy (AIT) with Subcutaneous Immunotherapy (SCIT) - Published for Review and Comments |
29094435 | Kirby Schwartzbauer | 02/10/2025 15:41:02 | Review of Cost Report Exhibit Templates Webinar - 03/20/2025 |
29041393 | Kirby Schwartzbauer | 02/10/2025 11:31:53 | Skin Substitutes - LCD Review Webinar - 09/18/2025 |
29093816 | Kirby Schwartzbauer | 02/10/2025 08:50:49 | Open Public Meeting Announcement - Allergy Immunotherapy (AIT) with Subcutaneous Immunotherapy (SCIT) - March 6, 2025 |
29095690 | James Marko | 02/11/2025 14:12:55 | CMS Telehealth Frequently Asked Questions (FAQ) |
29093752 | James Marko | 02/10/2025 08:46:22 | Billing and Coding: MolDX: Minimal Residual Disease Testing for Solid Tumor Cancers (A58456) - R9 - Effective November 18, 2024 |
29041379 | Kirby Schwartzbauer | 02/10/2025 11:31:50 | Skin Substitutes - LCD Review Webinar - 09/18/2025 |
29095709 | James Marko | 02/11/2025 14:12:56 | CMS Telehealth Frequently Asked Questions (FAQ) |
29093770 | James Marko | 02/10/2025 08:46:25 | Billing and Coding: MolDX: Minimal Residual Disease Testing for Solid Tumor Cancers (A58456) - R9 - Effective November 18, 2024 |
Article ID | Modified By | Modified On | Title |
---|---|---|---|
29095312 | Kirby Schwartzbauer | 02/11/2025 10:37:02 | Ventilators Webinar - 03/25/2025 |
29095208 | Kirby Schwartzbauer | 02/11/2025 10:32:09 | Therapeutic Shoes for Persons with Diabetes Webinar - 03/26/2025 |
29095343 | Kirby Schwartzbauer | 02/11/2025 11:12:39 | Continued Coverage for Continuous Glucose Monitor (CGM) |
Article ID | Modified By | Modified On | Title |
---|---|---|---|
29093734 | James Marko | 02/10/2025 08:46:19 | Billing and Coding: MolDX: Minimal Residual Disease Testing for Solid Tumor Cancers (A58454) - R9 - Effective November 18, 2024 |
29095675 | James Marko | 02/11/2025 14:12:55 | CMS Telehealth Frequently Asked Questions (FAQ) |
29095726 | James Marko | 02/11/2025 14:12:57 | CMS Telehealth Frequently Asked Questions (FAQ) |
29093942 | James Marko | 02/10/2025 10:11:52 | Allergen Immunotherapy (AIT) with Subcutaneous Immunotherapy (SCIT) - Published for Review and Comments |
29093788 | Kirby Schwartzbauer | 02/10/2025 08:50:47 | Open Public Meeting Announcement - Allergy Immunotherapy (AIT) with Subcutaneous Immunotherapy (SCIT) - March 6, 2025 |
29041351 | Kirby Schwartzbauer | 02/10/2025 11:31:43 | Skin Substitutes - LCD Review Webinar - 09/18/2025 |
29093802 | Kirby Schwartzbauer | 02/10/2025 08:50:48 | Open Public Meeting Announcement - Allergy Immunotherapy (AIT) with Subcutaneous Immunotherapy (SCIT) - March 6, 2025 |
29041365 | Kirby Schwartzbauer | 02/10/2025 11:31:46 | Skin Substitutes - LCD Review Webinar - 09/18/2025 |
29093960 | James Marko | 02/10/2025 10:11:52 | Allergen Immunotherapy (AIT) with Subcutaneous Immunotherapy (SCIT) - Published for Review and Comments |
29093716 | James Marko | 02/10/2025 08:46:17 | Billing and Coding: MolDX: Minimal Residual Disease Testing for Solid Tumor Cancers (A58454) - R9 - Effective November 18, 2024 |
29094421 | Kirby Schwartzbauer | 02/10/2025 15:41:06 | Review of Cost Report Exhibit Templates Webinar - 03/20/2025 |
Article ID | Modified By | Modified On | Title |
---|---|---|---|
29095357 | Kirby Schwartzbauer | 02/11/2025 11:12:39 | Continued Coverage for Continuous Glucose Monitor (CGM) |
29095194 | Kirby Schwartzbauer | 02/11/2025 10:32:13 | Therapeutic Shoes for Persons with Diabetes Webinar - 03/26/2025 |
29095298 | Kirby Schwartzbauer | 02/11/2025 10:36:59 | Ventilators Webinar - 03/25/2025 |